MOPHA (Qatar)

Qatar MoPH (Ministry of Public Health — State of Qatar) — operating through the Department of Pharmacy and Drug Control (DPDC) — is the State of Qatar's national regulatory authority for human medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + dietary supplements + pharmacy practice + controlled substances. Qatar MoPH operates under Law 7 of 2017 (Pharmacy Profession + Pharmaceutical Establishments — replacing earlier Law 3 of 1983 framework) + Law 9 of 1990 (Pharmacy Practice) + Law 9 of 1987 (Narcotics + Psychotropics — substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988) + Emiri Decrees + Ministerial Decisions + DPDC Decisions + Guidance Documents.

Qatar MoPH organisational structure includes:

• Minister of Public Health — political head appointed by Emiri Decree.
• Assistant Undersecretary for Pharmacy and Drug Control Affairs.
• Department of Pharmacy and Drug Control (DPDC) — pharmaceutical + medical-device + cosmetic + dietary-supplement regulator.
• Drug Registration Section — drug + biological + vaccine + biosimilar + generic-medicine registration.
• Pharmaceutical Inspection Section — GMP + GDP + GPP + GVP + GLP inspections of Qatari + foreign manufacturing facilities.
• Pharmacovigilance Section — Qatar National Pharmacovigilance Centre + WHO PIDM coordination.
• Medical Devices Section — medical-device + IVD registration + matériovigilance.
• Pharmacy Practice Section — pharmacy + pharmaceutical-establishment licensing.
• Cosmetics + Dietary Supplements Section — cosmetic-product + dietary-supplement notification.
• Controlled Substances Section — narcotics + psychotropics framework coordination with INCB + Ministry of Interior + Qatar Customs.
• International Affairs Section — WHO + EMA + FDA + GHC + Arab League + ICH coordination.
• Qatar Central Laboratory for Drug Control — central pharmaceutical QC laboratory; ISO/IEC 17025 accredited; pursuing WHO PQ-Lab designation.
• Qatar National Pharmacovigilance Centre — integrated PV + matériovigilance + cosmétovigilance centre.

Qatar MoPH is distinct from + complementary to: Hamad Medical Corporation (HMC — Qatar's primary public healthcare provider operating Hamad General Hospital + Rumailah Hospital + Women's Wellness and Research Center + National Center for Cancer Care and Research + Heart Hospital + Communicable Disease Center); Primary Health Care Corporation (PHCC — primary care network); Sidra Medicine (academic medical centre focused on women's and children's care + clinical research); Qatar Foundation Hamad Bin Khalifa University + Qatar Biomedical Research Institute (QBRI) + Qatar Genome Programme (QGP — biotechnology + genomics research); Qatar Petroleum healthcare (industry-specific healthcare); and Qatari pharmaceutical importer/distributor companies. Qatar's pharmaceutical environment is uniquely characterised by: predominantly expatriate population (~88% expatriate, ~12% Qatari national); exceptionally high-income healthcare expenditure per capita globally (~USD 2,500-3,000+ per capita); substantial pharmaceutical import dependency (~99% of pharmaceuticals imported — minimal domestic manufacturing); world-leading biotechnology + advanced-therapy + clinical-research focus disproportionate to population size via Sidra Medicine + QBRI + Qatar Genome Programme + Hamad Medical Corporation Translational Research Institute; + strategic Qatar National Vision 2030 + Qatar National Health Strategy 2018-2022 positioning Qatar as a regional health-research + biotechnology + clinical-trial hub.

Qatar MoPH is a Gulf Health Council (GHC) Member State authority + an active GCC Drug Registration co-leader (alongside SFDA + MoHAP + Kuwait MoH + Bahrain NHRA + Oman MoH — completing the six-Member-State GCC framework) + a League of Arab States Council of Arab Ministers of Health pharmaceutical-harmonisation co-leader + an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority + a PIC/S Pre-Accession Candidate + an ICH Observer Candidate + an IMDRF Observer + holds substantial bilateral cooperation with EMA + FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS.

Qatari pharmaceutical regulation operates under a layered framework of Laws + Emiri Decrees + Ministerial Decisions + DPDC Decisions + Guidance Documents:

• Law 7 of 2017 — Pharmacy Profession + Pharmaceutical Establishments framework (replacing earlier Law 3 of 1983).
• Law 9 of 1990 — Pharmacy Practice framework.
• Law 9 of 1987 — Narcotics + Psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988.
• Emiri Decrees + Ministerial Decisions on Medical Devices + Cosmetics + Dietary Supplements.
• DPDC GMP Guide — substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2 + GCC GMP.
• DPDC GDP Guide — substantively aligned with WHO + EU GDP + GCC GDP.
• DPDC GCP Guide — substantively aligned with ICH E6(R2) + GCC GCP — particularly substantial given Qatar's world-leading clinical-research capacity.
• DPDC GVP Guide — substantively aligned with ICH E2 + EU GVP + GCC GVP.
• GCC Pharmacopoeia + recognises British Pharmacopoeia + USP + European Pharmacopoeia + Arab Pharmacopoeia.
• GCC Drug Registration framework — substantively harmonised registration procedure across GCC Member States.
• DPDC Medical Devices framework — Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF + GCC-MD.
• DPDC Cosmetics framework — substantively aligned with EU Cosmetics Regulation including INCI ingredient listing + safety substantiation.
• DPDC Variations + 5-year Drug Registration Renewal framework.
• Qatar National Vision 2030 + Qatar National Health Strategy regulatory alignment.
• Qatar Biobank + Qatar Genome Programme + Qatar Research, Development & Innovation Council coordination on advanced-therapy + precision-medicine regulation.

The Qatar Central Laboratory for Drug Control is DPDC's central pharmaceutical + medical-device quality-control laboratory + is ISO/IEC 17025 accredited. The Laboratory is pursuing WHO PQ-Lab designation, which would position it alongside Saudi SFDA Central Laboratory + Egypt EDA NODCAR + Morocco LNCM + Tunisia LNCM + Jordan JFDA Central Laboratories as a WHO-prequalified pharmaceutical QC laboratory in the MENA region. Qatar additionally benefits from GCC Pharmaceutical Inspection cooperation — harmonised GCC-Member-State pharmaceutical inspection providing efficient cross-Member-State inspection coordination + reliance + recognition.

• ISO/IEC 17025 Accreditation — the Qatar Central Laboratory for Drug Control is ISO/IEC 17025 accredited across multiple testing scopes including pharmaceutical chemical + microbiological + biological testing.
• WHO PQ-Lab Candidate — the Laboratory is pursuing WHO PQ-Lab designation.
• GCC Pharmaceutical Inspection — Qatar participates in GCC harmonised pharmaceutical inspection providing efficient cross-Member-State inspection coordination + reliance + recognition with all five other GCC Member States.
• GCC Centralized Drug Registration — substantively harmonised registration procedure across all six GCC Member States.
• Vaccine lot release — the Laboratory conducts vaccine lot-release testing for DPDC + Qatar National Immunization Programme.
• Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + post-market surveillance + targeted enforcement testing.
• Medical-device + IVD testing — pre-market + post-market quality testing.
• Cosmetic-product + dietary-supplement testing — safety + ingredient compliance testing.
• Counterfeit-medicine forensics — forensic analytical support for DPDC + Qatar Customs + Ministry of Interior investigations + WHO Global Surveillance & Monitoring System contributions.
• Advanced-therapy testing — coordination with Sidra Medicine + QBRI + Qatar Genome Programme on cell-therapy + gene-therapy + tissue-engineered product testing.
• Capacity-building — hosts GHC + Arab League + WHO capacity-building programmes + training for GCC + Arab-region pharmaceutical analysts.
• GMP Inspectorate support — provides scientific + technical support for DPDC + GCC harmonised GMP inspections of Qatari + foreign manufacturing facilities.

DPDC medical-device + IVD regulation operates under DPDC Medical Devices framework with Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF + GCC-MD. Foreign manufacturers must appoint a Qatari Authorised Representative. Qatar's medical-device market is disproportionately advanced for its population size given the substantial capital-equipment installations at Hamad Medical Corporation + Sidra Medicine + Aspetar Orthopaedic and Sports Medicine Hospital.

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR + GHTF/IMDRF + GCC-MD; IVDs classified under separate Qatar IVD framework.
• Qatari Authorised Representative — Qatar-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + DPDC regulatory interface.
• ISO 13485:2016 — recognised by DPDC as QMS evidence framework; Qatar-specific overlay required.
• Reliance pathways — DPDC accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence; CE Mark + FDA particularly central.
• GCC Medical Devices Harmonisation — Qatar participates in GCC harmonised medical-device framework providing reliance + harmonised technical-file requirements across all six GCC Member States.
• Arab League Medical Devices Harmonisation — Qatar participates in Council of Arab Ministers of Health medical-device harmonisation.
• Post-market vigilance — DPDC operates medical-device adverse-event reporting through the Qatar Matériovigilance System coordinated by Qatar National Pharmacovigilance Centre; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• IVD Réactovigilance — DPDC operates IVD réactovigilance reflecting Qatar's exceptionally advanced clinical-laboratory infrastructure including Hamad Medical Corporation + Sidra Medicine + Aspetar + Weill Cornell Medicine-Qatar + Primary Health Care Corporation laboratory networks.
• Cosmetic Notification — cosmetics require DPDC Cosmetic Notification + Arabic + English labelling; INCI-aligned ingredient listing + safety substantiation; substantively EU-aligned framework.
• Dietary Supplement Registration — DPDC Dietary Supplements framework; substantively aligned with EU food-supplement framework + Codex Alimentarius.
• Qatar UDI — DPDC is progressively implementing UDI requirements substantively aligned with FDA UDI + EU EUDAMED UDI.
• Importation Permit — DPDC Importation Permit required in addition to product registration for foreign-manufactured devices + drugs entering Qatar; coordination with Qatar Customs + Ministry of Commerce and Industry.
• Advanced-therapy + cell-therapy + gene-therapy coordination — specialised pathways coordinated with Sidra Medicine + QBRI + Qatar Genome Programme.

DPDC operates the Qatar National Pharmacovigilance Programme through the Qatar National Pharmacovigilance Centre. Qatar is a WHO Programme for International Drug Monitoring (PIDM) member + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The Qatar National Pharmacovigilance Centre operates Qatar's integrated pharmacovigilance + matériovigilance + cosmétovigilance centre. Qatar's pharmacovigilance is substantially enhanced by Sidra Medicine + Hamad Medical Corporation + Qatar Genome Programme precision-medicine + pharmacogenomics-informed safety surveillance — providing one of the most genomically-informed national pharmacovigilance frameworks in the GCC + Arab region.

• Qatar National Pharmacovigilance Centre — integrated PV + matériovigilance + cosmétovigilance centre operating under DPDC Pharmacovigilance Section coordination.
• WHO PIDM Member — Qatar is a WHO PIDM member + contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• Qatar Pharmacovigilance Network — coordinated national network with effector centres in major Qatari hospitals (Hamad Medical Corporation hospitals, Sidra Medicine, Aspetar, Primary Health Care Corporation, Al Khor Hospital, Al Wakra Hospital, Cuban Hospital Dukhan, Qatar Petroleum Healthcare) + Marketing Authorisation Holders.
• Online ADR Reporting — DPDC operates online ADR reporting via the DPDC portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — DPDC accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); DPDC-specific submission timeline.
• Risk Management Plans (RMP) — DPDC requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — Qatar National PV Centre operates targeted active-surveillance programmes including for diabetes therapeutics + oncology + COVID-19 vaccines + biologicals + advanced therapies + sentinel-site hospital surveillance via Hamad Medical Corporation + Sidra Medicine sentinel networks.
• Pharmacogenomics-informed PV — distinctive pharmacogenomics-informed pharmacovigilance enabled by Qatar Genome Programme + Qatar Biobank + Sidra Medicine precision-medicine capabilities; one of few GCC + Arab-region jurisdictions with substantial pharmacogenomics infrastructure.
• AEFI Surveillance — Qatari vaccine adverse-event surveillance aligned with WHO methodology; central to Qatar National Immunization Programme + COVID-19 vaccine safety monitoring.
• Matériovigilance + Cosmétovigilance — DPDC operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics through the integrated National Pharmacovigilance Centre.
• GCC Pharmacovigilance Network — Qatar participates in GCC harmonised pharmacovigilance network providing efficient cross-Member-State safety signal sharing across all six Member States.
• Clinical-research safety integration — substantial integration with Qatar's world-leading clinical-research infrastructure providing rich clinical-trial + post-market safety signal capacity.

• WHO Listed Authority Candidate — DPDC is a WHO Listed Authority candidate; substantial WHO PQ CRP participation + WHO PIDM membership + GCC Drug Registration co-leadership + world-leading biotechnology + clinical-research focus support trajectory.
• WHO PQ CRP Participating Authority — DPDC is an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority.
• WHO PQ-Lab Candidate — Qatar Central Laboratory for Drug Control is pursuing WHO PQ-Lab designation.
• GHC Member State — Qatar MoPH is a Gulf Health Council (GHC) Member State authority + active GCC Drug Registration co-leader alongside Saudi SFDA + UAE MoHAP + Kuwait MoH + Bahrain NHRA + Oman MoH (completing the six-Member-State GCC framework).
• Arab League Council of Arab Ministers of Health Co-leader — DPDC is an active pharmaceutical-harmonisation co-leader alongside Egyptian EDA + Saudi SFDA + Jordanian JFDA + UAE MoHAP + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Lebanese MoH + Kuwait MoH + Bahrain NHRA + Oman MoH.
• EMA Bilateral — DPDC holds substantial bilateral cooperation with EMA covering information exchange + reliance + clinical-trial harmonisation + advanced-therapy regulatory science.
• FDA Bilateral — DPDC holds substantial cooperation with FDA reflecting US-Qatar pharmaceutical trade + Weill Cornell Medicine-Qatar US-medical-education ties + Sidra Medicine US-clinical-affiliation links.
• MHRA Bilateral — DPDC holds substantial cooperation with MHRA reflecting historical UK-Qatar regulatory cooperation (Qatar achieved independence from UK protectorate status in 1971) + UK-trained Qatari pharmaceutical professionals + Qatar Foundation-University College London partnership.
• Health Canada + TGA + Swissmedic + MFDS Bilateral — DPDC holds bilateral cooperation reflecting Stringent Regulatory Authority reliance practice.
• PIC/S Pre-Accession Candidate — DPDC is on PIC/S Pre-Accession Candidate trajectory; GMP Guide substantively aligned with PIC/S GMP + EU GMP + ICH Q7.
• ICH Observer Candidate — DPDC is exploring ICH Observer status; ICH guidelines extensively implemented in Qatari regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• IMDRF Observer — DPDC is an IMDRF Observer + draws on IMDRF guidance for medical-device regulation.
• ICDRA + EMRO participation — active International Conference of Drug Regulatory Authorities + WHO Eastern Mediterranean Regional Office (EMRO) participant.
• Qatar Genome Programme + Qatar Biobank international cooperation — substantial international cooperation on genomics + precision medicine + pharmacogenomics regulatory science.
• Sidra Medicine international academic-medical-centre cooperation — clinical-research + advanced-therapy regulatory cooperation with peer international academic medical centres.

• Qatari Authorised Representative not properly designated — application rejected at DPDC intake or post-approval compliance failure; Qatari Authorised Representative must be Qatar-resident legal entity with appropriate licensure.
• Arabic + English labelling deficiencies — Arabic + English labelling required; many applicants provide insufficient Arabic-language patient leaflet despite Qatar's predominantly expatriate population.
• DPDC + GCC GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Qatar-specific DPDC + GCC GMP clarifications.
• Qatar climate-zone stability data missing — Qatar is Climate Zone IVb (hot/humid coastal — Doha / Al Wakra / Al Khor) requiring substantial zonal-specific stability data particularly for Qatar summer ambient conditions (often >45°C with very high humidity).
• Bioequivalence centres + biowaiver — DPDC + GCC Biowaiver Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated DPDC CRP review (90-day target); under-utilised by many applicants.
• GCC Drug Registration reliance under-utilised — GCC harmonised registration procedure provides substantial acceleration; under-utilised by many applicants.
• EMA bilateral reliance under-utilised — DPDC-EMA cooperation provides substantial acceleration for EMA-approved products.
• FDA / Health Canada / TGA / Swissmedic / MHRA / MFDS reliance under-utilised — DPDC operates substantial reliance on Stringent Regulatory Authority decisions; particularly FDA reliance reflecting Weill Cornell Medicine-Qatar + Sidra Medicine US-affiliation links + MHRA reliance reflecting historical UK-Qatar cooperation.
• Arab League harmonisation not leveraged — Council of Arab Ministers of Health pharmaceutical-harmonisation reliance under-utilised.
• Advanced-therapy + precision-medicine pathway not leveraged — applicants frequently overlook Qatar's distinctive advanced-therapy + precision-medicine pathway coordinated with Sidra Medicine + QBRI + Qatar Genome Programme + Qatar Biobank; one of few GCC + Arab-region jurisdictions with substantial advanced-therapy regulatory infrastructure.
• Essential Medicines + Vital Medicines accelerated pathway not leveraged — accelerated Registration under-utilised; 90-120 working day target.
• Hamad Medical Corporation + Sidra Medicine procurement strategy missing — Qatar's substantial public-sector pharmaceutical procurement via HMC + Sidra Medicine + Primary Health Care Corporation requires specific procurement-strategy planning frequently overlooked.
• Pharmacogenomics-informed labelling missed — Qatar's distinctive pharmacogenomics infrastructure via Qatar Genome Programme + Qatar Biobank enables pharmacogenomics-informed labelling + post-market surveillance frequently overlooked by foreign manufacturers.
• Variations strategy not planned — variations procedure substantively similar to EU + GCC but with Qatar-specific timelines + fee structure.
• Registration renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.
• Clinical trial ethics coordination steps — Qatar clinical trials require DPDC CTA + relevant Institutional Review Board (Hamad Medical Corporation Medical Research Center IRB / Sidra Medicine IRB / Qatar Biomedical Research Institute IRB / Weill Cornell Medicine-Qatar IRB) approval; Qatar's world-leading clinical-research capacity provides substantial opportunity frequently overlooked by sponsors.

V5 Ultimate provides the operational infrastructure Qatari + foreign-supplier sites need for Law 7 of 2017 + Law 9 of 1990 + DPDC + GCC GMP + Medical Devices framework + WHO PQ CRP + EMA bilateral + GHC + Arab League + Qatar National Pharmacovigilance Programme + Hamad Medical Corporation + Sidra Medicine procurement + advanced-therapy + precision-medicine pathway readiness.

• DPDC + GCC GMP control framework — PIC/S + EU GMP + ICH Q7 + GCC GMP-aligned controls with ALCOA+ data-integrity + Qatar-specific clarifications + Climate Zone IVb stability monitoring.
• DPDC Registration dossier packaging — Qatar CTD-aligned dossier structure with Qatar Module 1 specifics + Module 3 stability + Arabic + English patient leaflet + Authorised Representative declarations + Law 7 of 2017 + Law 9 of 1990 framework.
• WHO PQ CRP workflow — DPDC-as-CRP-participating-authority packaging with reduced dossier + accelerated DPDC review (90-day target).
• GCC Drug Registration workflow — GCC harmonised registration procedure packaging supporting cross-Member-State market access across all six GCC Member States — completed coverage with Qatar MoPH.
• EMA bilateral reliance workflow — DPDC-EMA cooperation packaging for EMA-approved products including advanced-therapy regulatory cooperation.
• FDA / Health Canada / TGA / Swissmedic / MHRA / MFDS reliance workflow — Stringent Regulatory Authority reliance packaging particularly FDA reliance reflecting Weill Cornell Medicine-Qatar + Sidra Medicine US-affiliation links + MHRA reliance reflecting historical UK-Qatar cooperation.
• Arab League workflow — Council of Arab Ministers of Health pharmaceutical-harmonisation packaging.
• Advanced-therapy + precision-medicine workflow — Qatar's distinctive Sidra Medicine + QBRI + Qatar Genome Programme + Qatar Biobank coordinated advanced-therapy + cell-therapy + gene-therapy + tissue-engineered-product + pharmacogenomics packaging.
• Hamad Medical Corporation + Sidra Medicine procurement workflow — Qatar's substantial public-sector pharmaceutical procurement via HMC + Sidra Medicine + Primary Health Care Corporation packaging.
• Essential Medicines + Vital Medicines accelerated workflow — Qatar National Essential Medicines List + public-health emergency product packaging.
• Qatari Authorised Representative workflow — foreign-manufacturer Authorised Representative designation + role-management + Qatar-specific post-market surveillance.
• Qatari clinical-trial workflow — DPDC CTA + Hamad Medical Corporation Medical Research Center IRB / Sidra Medicine IRB / QBRI IRB / Weill Cornell Medicine-Qatar IRB coordination + Qatar SUSAR reporting via Qatar National PV Centre; leverages Qatar's world-leading clinical-research capacity.
• Qatar National PV Centre Pharmacovigilance integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Arabic + English ICSR + Qatar PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting + distinctive pharmacogenomics-informed surveillance.
• Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging coordinated through Qatar National PV Centre.
• Medical-device + IVD + cosmetic + dietary-supplement workflow — DPDC frameworks dossier packaging + Class I-III classification + ISO 13485 + Authorised Representative + post-market vigilance.
• Qatar National Vision 2030 alignment — Qatar National Vision 2030 + Qatar National Health Strategy + biotechnology + advanced-therapy + clinical-research + precision-medicine alignment.
• Complete GCC + Arab League regional bridging — for companies operating across GCC + MENA, V5 surfaces DPDC + Saudi SFDA + UAE MoHAP + Kuwait MoH + Bahrain NHRA + Oman MoH + Jordan JFDA + Egyptian EDA + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP harmonised dossier-element reuse alongside national-specific extensions — completing six-Member-State GCC + multi-Arab-League coverage.